A detailed history of Federated Hermes, Inc. transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 5,677 shares of ARWR stock, worth $111,439. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,677
Previous 7,201 21.16%
Holding current value
$111,439
Previous $187,000 41.71%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$19.36 - $29.54 $29,504 - $45,018
-1,524 Reduced 21.16%
5,677 $109,000
Q2 2024

Aug 08, 2024

SELL
$21.87 - $28.24 $164,834 - $212,844
-7,537 Reduced 51.14%
7,201 $187,000
Q1 2024

May 14, 2024

BUY
$27.21 - $39.48 $198,850 - $288,519
7,308 Added 98.36%
14,738 $421,000
Q4 2023

Jan 31, 2024

SELL
$21.2 - $31.03 $34,407 - $50,361
-1,623 Reduced 17.93%
7,430 $227,000
Q3 2023

Nov 13, 2023

SELL
$26.2 - $36.08 $40,426 - $55,671
-1,543 Reduced 14.56%
9,053 $243,000
Q2 2023

Aug 14, 2023

BUY
$25.16 - $41.38 $26,543 - $43,655
1,055 Added 11.06%
10,596 $377,000
Q1 2023

May 08, 2023

SELL
$23.68 - $38.51 $50,391 - $81,949
-2,128 Reduced 18.24%
9,541 $242,000
Q4 2022

Feb 13, 2023

SELL
$28.0 - $40.56 $178,472 - $258,529
-6,374 Reduced 35.33%
11,669 $473,000
Q3 2022

Nov 14, 2022

BUY
$29.63 - $48.31 $135,557 - $221,018
4,575 Added 33.97%
18,043 $596,000
Q2 2022

Aug 15, 2022

SELL
$27.79 - $50.61 $262,282 - $477,657
-9,438 Reduced 41.2%
13,468 $475,000
Q1 2022

May 13, 2022

BUY
$39.62 - $69.97 $146,158 - $258,119
3,689 Added 19.2%
22,906 $1.05 Million
Q4 2021

Feb 14, 2022

SELL
$58.09 - $82.51 $195,937 - $278,306
-3,373 Reduced 14.93%
19,217 $1.27 Million
Q3 2021

Nov 15, 2021

SELL
$58.38 - $84.96 $3.2 Million - $4.65 Million
-54,757 Reduced 70.79%
22,590 $1.41 Million
Q2 2021

Aug 16, 2021

BUY
$62.15 - $90.32 $113,050 - $164,292
1,819 Added 2.41%
77,347 $6.41 Million
Q1 2021

May 13, 2021

BUY
$61.35 - $90.47 $1.35 Million - $1.99 Million
22,018 Added 41.15%
75,528 $5.01 Million
Q4 2020

Feb 12, 2021

BUY
$43.82 - $85.37 $1.53 Million - $2.99 Million
34,971 Added 188.63%
53,510 $4.11 Million
Q3 2020

Nov 12, 2020

SELL
$33.21 - $51.27 $547,666 - $845,493
-16,491 Reduced 47.08%
18,539 $798,000
Q2 2020

Aug 13, 2020

SELL
$26.12 - $43.27 $4.17 Million - $6.91 Million
-159,678 Reduced 82.01%
35,030 $1.51 Million
Q1 2020

May 13, 2020

SELL
$20.56 - $63.12 $2.3 Million - $7.06 Million
-111,867 Reduced 36.49%
194,708 $5.6 Million
Q4 2019

Feb 14, 2020

BUY
$28.14 - $73.01 $5.45 Million - $14.1 Million
193,552 Added 171.25%
306,575 $19.4 Million
Q3 2019

Nov 14, 2019

SELL
$26.26 - $34.86 $398,863 - $529,488
-15,189 Reduced 11.85%
113,023 $3.19 Million
Q2 2019

Aug 14, 2019

BUY
$17.43 - $28.82 $2.22 Million - $3.66 Million
127,157 Added 12052.8%
128,212 $3.4 Million
Q1 2019

May 10, 2019

BUY
$12.05 - $20.18 $4,350 - $7,284
361 Added 52.02%
1,055 $19,000
Q4 2018

Feb 13, 2019

SELL
$10.74 - $19.7 $1.25 Million - $2.3 Million
-116,506 Reduced 99.41%
694 $8,000
Q3 2018

Nov 13, 2018

BUY
$14.0 - $20.3 $1.25 Million - $1.81 Million
89,055 Added 316.41%
117,200 $2.25 Million
Q2 2018

Aug 10, 2018

BUY
$6.37 - $14.02 $173,302 - $381,428
27,206 Added 2897.34%
28,145 $383,000
Q1 2018

May 09, 2018

BUY
$3.72 - $7.64 $3,493 - $7,173
939 New
939 $7,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.08B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.